The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Multicenter phase II study of FOLFOX or biweekly XELOX and cetuximab as first-line treatment in patients with wild-type KRAS/BRAF metastatic colorectal cancer (mCRC) (FLEET study).
Ho Min Kim
No relevant relationships to disclose
Hitoshi Soda
No relevant relationships to disclose
Shoichi Hazama
No relevant relationships to disclose
Takao Takahashi
No relevant relationships to disclose
Naoki Nagata
No relevant relationships to disclose
Masahito Kotaka
No relevant relationships to disclose
Emiko Kono
No relevant relationships to disclose
Itsurou Terada
No relevant relationships to disclose
Mutsumi Fukunaga
No relevant relationships to disclose
Koji Oba
No relevant relationships to disclose
Junichi Hasegawa
No relevant relationships to disclose
Junichi Sakamoto
No relevant relationships to disclose
Hideyuki Mishima
No relevant relationships to disclose